Etude in vitro et in vivo de deux héparines de bas poids moléculaire microencapsulées de rapports anti-Xa/anti-IIa différents : la nadroparine et la tinzaparine

Etude in vitro et in vivo de deux héparines de bas poids moléculaire microencapsulées de rapports anti-Xa/anti-IIa différents : la nadroparine et la tinzaparine

Des microparticules d’héparine de bas poids moléculaire (HBPM) ont été fabriquées suivant la méthode de la double émulsion à partir d’un polymère non biodégradable polycationique (Eudragit® RS) utilisé seul ou en mélange à différents pourcentages avec un polymère biodégradable (acide poly(lactique-c...

Full description

Bibliographic Details
Main Author:	Javot, Lucie
Other Authors:	Nancy 1
Language:	fr
Published:	2009
Subjects:	Rapport anti-Xa/anti-IIa Microparticules
Online Access:	http://www.theses.fr/2009NAN10093/document

Similar Items

DEVELOPMENT, VALIDATION AND APPLICATION OF ANTI-Xa- AND ANTI-IIa-ENOXAPARINE SODIUM ASSAY
by: B. Yu. Margaeva, et al.
Published: (2019-01-01)

The anti-factor Xa range for low molecular weight heparin thromboprophylaxis
by: Matthew Y. Wei, et al.
Published: (2015-11-01)

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
by: Tahaineh L, et al.
Published: (2018-05-01)

Biological potency evaluation and physicochemical characterization of unfractionated heparins Avaliação biológica de potência e caracterização físico-química de heparinas não fracionadas
by: Sérgio L. Dalmora, et al.
Published: (2009-01-01)

Direct oral anticoagulant blood level monitoring in daily practice
by: R. Bavalia, et al.
Published: (2021-05-01)

Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients
by: Pavlović Svetlana, et al.
Published: (2007-01-01)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
by: Kozue Ikeda, MD, et al.
Published: (2016-02-01)

Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases
by: Guo R, et al.
Published: (2020-11-01)

Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery
by: Florian Wilhelmy, et al.
Published: (2021-05-01)

Does atorvastatin therapy change the anti‐Xa activity in xabans‐treated patients with atrial fibrillation?
by: Ingrid Škorňová, et al.
Published: (2021-05-01)

Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range
by: N V Seredavkina, et al.
Published: (2019-05-01)

Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study
by: Wenxin Bai, et al.
Published: (2021-10-01)

Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with direct oral anticoagulant
by: Makoto Ikejiri, et al.
Published: (2017-10-01)

In vivo real-time monitoring of anti-factor Xa level using a microdialysis-coupled microfluidic device
by: Xingbei Zhou, et al.
Published: (2021-12-01)

Apixaban anti-Xa level monitoring in treatment of acute upper extremity deep vein thrombosis for patient on chronic hemodialysis: a case report
by: Guillaume Roberge, et al.
Published: (2021-04-01)

Assessing Anticoagulation in Neonates With Congenital Diaphragmatic Hernia During Extracorporeal Membrane Oxygenation: Does Anti-Factor Xa or Thromboelastometry Provide Additional Benefit?
by: Alba Perez Ortiz, et al.
Published: (2021-09-01)

Efficacy and tolerance of selective and non-selective factor Xa inhibitors in the prevention of thrombosis in kidney disease in patients with systemic lupus erythematosus and antiphospholipid syndrome
by: N. V. Seredavkina, et al.
Published: (2019-03-01)

Anti–factor Xa activity assays of direct‐acting oral anticoagulants during clinical care: An observational study
by: Smrithi Sukumar, et al.
Published: (2021-05-01)

Développement de formes orales d'héparine et de formes à libération prolongée de warfarine : Une réponse à l'amélioration de la prévention de la thrombose ?
by: Scala-Bertola, Julien
Published: (2009)

Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): a multicenter cohort study
by: Richard Descamps, et al.
Published: (2021-04-01)

Isolation and Characterization of Plantaricin Produced by Lactobacillus plantarum Strains (IIA-1A5, IIA-1B1, IIA-2B2)
by: I. I. Arief, et al.
Published: (2013-08-01)

Anti-Adipogenic Effects on 3T3-L1 Cells and Zebrafish by Tanshinone IIA
by: Yu-Kyoung Park, et al.
Published: (2017-09-01)

Tanshinone IIA Exerts Anti-Inflammatory and Immune-Regulating Effects on Vulnerable Atherosclerotic Plaque Partially via the TLR4/MyD88/NF-κB Signal Pathway
by: Zhuo Chen, et al.
Published: (2019-07-01)

A Single-Tube, Functional Marker-Based Multiplex PCR Assay for Simultaneous Detection of Major Bacterial Blight Resistance Genes Xa21, xa13 and xa5 in Rice
by: S.K. Hajira, et al.
Published: (2016-05-01)

Comparative laboratory effectiveness of low molecular weight heparins in patients with acute coronary syndrome and no ST segment elevation
by: R. M. Linchak, et al.
Published: (2011-02-01)

Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO
by: Alexander S. Streng, et al.
Published: (2020-10-01)

Heparins: A Shift of Paradigm
by: H. Coenraad Hemker, et al.
Published: (2019-11-01)

Characterization and Stability of Tanshinone IIA Solid Dispersions with Hydroxyapatite
by: Weiguang Li, et al.
Published: (2013-03-01)

Evaluation of Tanshinone IIA Developmental Toxicity in Zebrafish Embryos
by: Tao Wang, et al.
Published: (2017-04-01)

Prophylactic anti-coagulation after severe burn injury in critical care settings
by: Megan Blake, et al.
Published: (2019-05-01)

Enoxaparin Utilization Evaluation and Its Clinical and Laboratory Outcomes in Pediatric Patients in a Children’s Teaching Hospital
by: Uldooz Samadi Bahrami, et al.
Published: (2020-09-01)

Microparticules à libération prolongée et réduisant la libération intiale prématurée
by: Sheikh Hassan, Ahmed
Published: (2008)

Survival analysis of Stage IIA1 and IIA2 cervical cancer patients
by: Jerry Cheng-Yen Lai, et al.
Published: (2013-03-01)

Molecular marker validation for bacterial leaf blight resistant genes Xa21 and Xa4 in Ld 99-12- 38 / IRBB 60 genetic background
by: W. D. P. Weerasinghe, et al.
Published: (2017-12-01)

Microparticules à libération contrôlée : nouveaux polymères et importance des conditions de libération
by: Delplace, Céline
Published: (2012)

The Role of Secretogranin-IIa and Its Derived Peptide Secretoneurin a in Feeding Regulation in Female Goldfish
by: Mikwar, Myy
Published: (2014)

The Role of Secretogranin-IIa and Its Derived Peptide Secretoneurin a in Feeding Regulation in Female Goldfish
by: Mikwar, Myy
Published: (2014)

A comprehensive review of tanshinone IIA and its derivatives in fibrosis treatment
by: Zhangyang Bi, et al.
Published: (2021-05-01)

Contraintes mécaniques et microparticules endothéliales
by: Vion, Anne-Clémence
Published: (2012)

Analysis of tanshinone IIA induced cellular apoptosis in leukemia cells by genome-wide expression profiling
by: Liu Chang, et al.
Published: (2012-01-01)